MeSH tree: C04.588.894.797.520.109.220.249
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival (EFS) in patients with resectable early-stage non-small ...
Oct 22, 2023
0
56
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumor cells, with less need for chemotherapy, following results of multiple clinical trials reported ...
Oct 18, 2023
0
40
In a recent study led by Ravi Salgia, M.D., Ph.D., the Arthur & Rosalie Kaplan Chair in Medical Oncology, a team of researchers from City of Hope, one of the largest cancer research and treatment organizations in the United ...
Oct 14, 2023
0
109
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), ...
Sep 14, 2023
0
66
A study presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer revealed that key reproductive factors such as early menopause, shortened reproductive span, and early age ...
Sep 12, 2023
0
37
A new editorial paper titled "Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer" has been published in Oncotarget.
Sep 11, 2023
0
35
Research findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival ...
Sep 9, 2023
0
63
The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according ...
Sep 9, 2023
0
69
Fresh discoveries about a certain type of immune cell could give lung cancer patients a more accurate prognosis and better identify who will benefit from immunotherapies.
Aug 30, 2023
0
46
For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compared to single-agent chemotherapy, according ...
Aug 15, 2023
0
32
